Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA
A Phase II Multicenter Randomized Study of Eltrombopag Combined With Cyclosporine and hATG Versus hATG and CsA as First Line Treatment in Pediatric Patients With Severe Acquired Aplastic Anemia
Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Listed as NCT03413306, this PHASE3 trial focuses on Acquired Aplastic Anemia and remains ongoing. Sponsored by Federal Research Institute of Pediatric Hematology, Oncology and Immunology, it has been updated 9 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Apr 2023 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Apr 2021 — Apr 2023 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jun 2018 — Nov 2019 [monthly]
Recruiting PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
For direct contact, visit the study record on ClinicalTrials.gov .